| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a80cbaaeee718664126e579cf4e41c2 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-405 |
| filingDate |
2018-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0843fcbd22665ace432430efe12f5efe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1b1afe59f653240a124bbfcf6264220
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0dbcc7f4b4d5333f54cf6c92b6eee7e |
| publicationDate |
2018-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2018201219-A1 |
| titleOfInvention |
Melatonin agonist treatment |
| abstract |
This invention provides methods of administering (1 R-trans)-N-[[2-(2,3 dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide as a melatonin receptor agonist to a human subject to treat or prevent a circadian rhythm disorder or sleep disorder. |
| priorityDate |
2006-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |